Arsenic trioxide Accord 1 mg/ml concentrate for solution for infusion, QTX-2101 clinical trials

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

This study is testing a new drug, QTX-2101, combined with a standard treatment for a type of blood cancer called Acute Promyelocytic Leukemia (APL). It aims to see how safe and effective this new combination is for people who have just been diagnosed.